PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
TI  - Trough DPP-4 Inhibition Differs between the Approved DPP-4 Inhibitors
DP  - 2013 Dec 01
TA  - MD Conference Express
PG  - 22--23
VI  - 13
IP  - 17
4099  - http://mdc.sagepub.com/content/13/17/22.2.short
4100  - http://mdc.sagepub.com/content/13/17/22.2.full
AB  - A pharmacodynamics study in patients with type 2 diabetes mellitus (T2DM) reveals that sitagliptin QD provides greater inhibition of dipeptidyl peptidase-4 (DPP-4) through the dosing interval (ie, measured at trough, 24 hours following the last morning dose) than either saxagliptin 5 mg QD or vildagliptin 50 mg QD and similar DPP-4 inhibition to vildagliptin 50 mg BID. The findings come from a randomized, placebo-controlled, open-label, crossover study.